Monsur K A, Hossain M S, Huq F, Rahaman M M, Haque M Q
J Infect Dis. 1975 Jan;131(1):40-3. doi: 10.1093/infdis/131.1.40.
A controlled study of the efficacy of cytosine arabinoside in the treatment of patients with variola major was performed. Cytosine aravinoside was given intravenously at a dose approximating 3 mg/kg of body weight every 24 hr for up to seven days. All nine patients receiving cytosine arabinoside and four of the 11 patients receiving placebo died. In three of the patients receiving cytosine aravinoside, death occurred late in the illness at a time when the patient's lesions began to dry up, the patient's temperature became normal, and the patient's general condition appeared to improve. The virus could be isolated from the blood at day 7 from three of four patients treated with cytosine arabinoside as compared with zero of six control patients. Hematologic data showed a depression in the number of circulating granulocytes. It is possible that the drug lowered the resistance to infection either through direct suppression of granulocytes or through interference with other immune mechanisms. Cytosine arabinside administered in the doses used in this study is not effective in the treatment of variola major.
进行了一项关于阿糖胞苷治疗重症天花患者疗效的对照研究。阿糖胞苷以约3毫克/千克体重的剂量静脉给药，每24小时一次，持续长达7天。接受阿糖胞苷治疗的9名患者和接受安慰剂治疗的11名患者中的4名均死亡。在接受阿糖胞苷治疗的3名患者中，死亡发生在疾病后期，此时患者的病变开始干涸，体温恢复正常，一般状况似乎有所改善。在接受阿糖胞苷治疗的4名患者中，有3名在第7天血液中可分离出病毒，而6名对照患者中则为零。血液学数据显示循环粒细胞数量减少。该药物可能通过直接抑制粒细胞或干扰其他免疫机制而降低了对感染的抵抗力。本研究中使用的剂量的阿糖胞苷对治疗重症天花无效。
